Report of the first world transplant congress

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 2, 2007, Pages 393-400

  Cravedi, Paolo ^a,b   Noris, Marina ^b   Remuzzi, Giuseppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b Transplant Research Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; ORGAN TRANSPLANTATION;

ANIMALS; CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 34548829926     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03421006     Document Type: Article

References (71)

1. Legorreta AP, Gilmore AS, Marehbian J: The relationship between induction therapy and acute rejection in renal transplant patients receiving a calcineurin inhibitor, mycophenolic acid, and steroid regimen [Abstract]. Am J Transplant 6[Suppl 21: 484, 2006
2. Webster AC, Playford EG, Higgins G, Chapman JR, Craig J: Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 1: CD003897, 2004
3. Szczech LA, Berlin JA, Feldman HI: The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 128: 817-826, 1998
4. Chuang P, Buchanan C, Kizikisik T, Schaefer H, Chakravarty A, Helderman JH, Nylander W, Shaffer D, Langone AJ: A non randomized, retrospective review of Simulect versus Thymoglobulin as induction agents for kidney transplantation at a single transplant center [Abstract]. Am J Transplant 6[Suppl 21: 829, 2006
5. Alloway R, Woodle ES, Gaber AO, Pirsch J, Shihab F, Van Veldhuisen P, Gao J, First MR, Holman J, Fitzsimmons W, Reisfield R: Multivariate analysis of risk factors for acute rejection with early (7 days) corticosteroid withdrawal: Results from a randomized, double blind, placebo-controlled trial [Abstract]. Am J Transplant 6[Suppl 2]: 257, 2006
6. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gomez-Sanchez MA, Lage E, Manito N, Alonso-Pulpon L: A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 81: 1542-1548, 2006
7. Steve Woodle E, Gaber AO, Shihab F, Pirsch J, First MR, Fitzsimmons W, Holman J, Reisfield R: Comparison of T cell depleting and non-T cell depleting antibody induction therapy for early corticosteroid withdrawal regimens [Abstract]. Am J Transplant 6[Suppl 2]: 353, 2006
8. Wong W, Agrawal N, Pascual M, Hirsch HH, Cosimi AB, Tolkoff-Rubin N: Use of thymoglobulin induction decreases acute rejection rate in living unrelated kidney transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 513-514, 2006
9. Pruchnic T, Solis D, Bowers V, LeFor W, Tabatabai F, Lopez-Cepero M: Thymoglobulin induction and its effects on acute rejection episodes in kidney transplant patients with sCD30 levels, DGF and/or ATN [Abstract]. Am J Transplant 6[Suppl 2]: 812, 2006
10. Mezrich JD, Djamali A, Pirsch JD, Chin T, Becker YT, Becker BN, Voss B, Leverson GE, Knechtle SJ, Sollinger HW, Samaniego MD: Effect of induction therapy on recurrence of autoimmune disease after kidney transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 1060, 2006
11. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, Bozorgzadeh A, Sanz I, Briggs BJ: Polyclonal rabbit anti-thymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79: 1507-1515, 2005
12. Lopez MC, Albin MJ, Clarkson MR, Sayegh MH, Najafian N: Ex vivo expansion of CD4+CD25+ immunoregulatory T cells by anti-thymocyte globulin [Abstract]. Am J Transplant 6[Suppl 2]: 170, 2006
13. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N: A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 17: 2844-2853, 2006
14. Khauli RB, Houjaij AH, Sawah SI, El-Hout YZ, Medawar W, Daouk M, Uwaydah M, Abdelnoor A: A prospective evaluation of low dose versus high dose single bolus anti-thymocyte globulin induction therapy in mismatched living-unrelated kidney transplants [Abstract]. Am J Transplant 6[Suppl 2]: 520, 2006
15. Arbogast HP, Illner WD, Hoffmann JN, Guba M, Fischereder M, Wimmer CD, Land WG, Jauch KW: Efficacy and safety of a combined polyclonal-monoclonal induction regime (PUMUCKL) in renal transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 293, 2006
16. Ciancio G, Sageshima J, Burke GW, Gaynor JJ, Roth D, Kupin W, Quintini C, Herrada E, Warque M, Rosen A, Miller J: A randomized trial comparing tacrolimus/mycophenolate mofetil (CellCept) versus tacrolimus/ enteric-coated mycophenolate sodium (Myfortic) in first renal transplants induced with both daclizumab and Thymoglobulin with steroid avoidance [Abstract]. Am J Transplant 6[Suppl 2]: 319, 2006
17. Ruggenenti P, Codreanu I, Cravedi P, Perna A, Gotti E, Remuzzi G: Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: A possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 1: 546-554, 2006
18. Nelson BH, Willeford DM: Biology of the interleukin-2 receptor. Adv Immunol 70: 1-81, 1998
19. Baan CC, Klepper M, Ijzermans JNM, Weimar W: Prospective analysis of functional Foxp3+CD4+CD25 bright+ regulatory T-cells in anti-CD25 treated kidney transplant recipients [Abstract]. Am J Transplant 6[Suppl 2]: 1055-1056, 2006
20. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo J, Frei U, Vanrenterghem Y, Daloze P, Halloran P: SYMPHONY: Comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 83, 2006
21. Vincenti F, Friman S, Scheuermann E, Rostaing L: Glucose metabolism disorders after renal transplantation: Results of an international, randomized trial comparing cyclosporine versus tacrolimus [Abstract]. Am J Transplant 6[Suppl 2]: 83, 2006
22. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60: 225-232, 1995
23. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
24. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325, 1995
25. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, Leichtman AB: Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 6: 1111-1131, 2006
26. Shah S, Collett D, Johnson R, Thuraisingham RC, Raftery MJ, Rudge C, Yaqoob MM: Long term graft outcome with MMF and azathioprine: A paired kidney analysis [Abstract]. Am J Transplant 6[Suppl 2]: 433, 2006
27. Shah S, Collett D, Johnson R, Thuraisingham RC, Raftery MJ, Rudge CJ, Yaqoob MM: Long-term graft outcome with mycophenolate mofetil and azathioprine: A paired kidney analysis. Transplantation 82: 1634-1639, 2006
28. Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, Gherardi G, Donati D, Salvadori M, Sandrini S, Valente U, Segoloni G, Mourad G, Federico S, Rigotti P, Sparacino V, Bosmans JL, Perico N, Ruggenenti P: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. Lancet 13; 364: 503-512, 2004
29. Wang K, Zhang H, Li Y, Wei Q, Li H, Yang Y, Lu Y: Efficacy of mycophenolate mofetil versus azathioprine after renal transplantation: A systematic review. Transplant Proc 36: 2068-2070, 2004
30. Mercadal L, Foltz V, Isnard-Bagnis C, Ourahma S, Deray G: Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient. Transplant Proc 37: 4241-4243, 2005
31. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338: 1813-1821, 1998
32. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ: Rational development of LEA 29Y (Belatacept), a high-affinity variant of CTLA4-Ig with potent inummosuppressive properties. Am J Transplant 5: 443-453, 2005
33. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B: Costimulation blockade with Belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005
34. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440, 2000
35. Gross DM, Belingheri M, Vincenti F, Bluestone JA: Enhanced regulatory T cell infiltration of renal allografts in the presence of costimulatory blockade with Belatacept [Abstract]. Am J Transplant 6[Suppl 2]: 375, 2006
36. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M: Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353: 2342-2351, 2005
37. Augustine JJ, Poggio ED, Clemente MJ, Aeder MI, Schulak JA, Heeger PS, Hricik DE: Towards individualized treatment of kidney transplant of kidney transplant recipients: Pretransplant anti donor cellular immunity by IFN-g ELISPOT identifies candidates that can most benefit from induction therapy [Abstract]. Am J Transplant 6[Suppl 2]: 649, 2006
38. Hernandez-Fuentes M, Sawitszki B, Sagoo P, Rovis F, Jimenez E, Perucha E, Le Moine A, Craciun L, Peters B, Braudeau C, Brouard S, Trzonkowski P, Warnecke G, Chapman S, Libin M, Warrens A, Goldman M, Volk HD, Soulillou JP, Janssen U, Wood K, Lechler RI: Indices of tolerance: Interim report [Abstract]. Am J Transplant 6[Suppl 2]: 403, 2006
39. Sottong PR, Rosebrock JA, Britz JA, Kramer TR: Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 7: 307-311, 2000
40. Thai N, Blisard D, Basu A, Tom K, Tan H, Bentlejewski C, Glidewell J, Britz: J, Kowaski R, Marcos A, Shapiro R, Zeevi A: Pancreas transplantation under Campath-1H and tacrolimus: Correlation between low T cell responses and infection [Abstract]. Am J Transplant 6[Suppl 2]: 104, 2006
41. Valero R, Sanchez-Velasco P, Rodrigo E, Ruiz JC, Leyva F, Arias M: Assessment about risk of infection in kidney transplant by measuring the concentration of ATP from CD4 cells following stimulation by CYLEX [Abstract]. Am J Transplant 6[Suppl 21: 486, 2006
42. Tantravahi J, Womer KL, Kaplan B: Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 58: 369-385, 2007
43. Vo AA, Wechsler E, Jagolino J, Lukovsky M, Sani S, Toyoda M, Peng A, Puliyanda D, Jordan SC: Monitoring for infectious complications of Campath-1H and Rituxan induction therapy in crossmatch (CMX) positive kidney transplant patients receiving intravenous gammaglobulin desensitization [Abstract]. Am J Transplant 6[Suppl 2]: 122, 2006
44. Kuchroo VK, Meyers JH, Umetsu DT, Dekruyff RH: TIM family of genes in immunity and tolerance. Adv Immunol 91: 227-249, 2006
45. de Souza AJ, Oriss TB, O'Malley KJ, Ray A, Kane LP: T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc Natl Acad Sci U S A 102: 17113-17118, 2005
46. Degauque N, Mariat C, Kenny J, Zhang D, Balasubramanian S, Soo Lee J, Xiao Zheng X, Strom T: TIM-1 pathway constitute a new first signal pathway for T cell [Abstract]. Am J Transplant 6[Suppl 2]: 253-254, 2006
47. Mariat C, Degauque N, Kenny J, Zhang D, Alexopoulos S, Gao W, Xao Zheng X, Strom TB: TIM-1 strengthens TH-1 polarization and weakens CD4+CD25+ T cell-regulation of the allo-immune response [Abstract]. Am J Transplant 6[Suppl 2]: 81, 2006
48. Litman GW, Cannon JP, Dishaw LJ: Reconstructing immune phylogeny: New perspectives. Nat Rev Immunol 5: 866-879, 2005
49. Goldstein DR, Tesar BM, Akira S, Lakkis FG: Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 111: 1571-1578, 2003
50. Chen L, Wang T, Ping Z, Ma L, Yin D, Shen J, Molinero L, Nozaki T, Phillips T, Wang C, Fairchild R, Alegre M, Chong A: TLR signals inhibit transplantation tolerance by preventing intra-graft recruitment of CD4+ Foxp3+ T cells [Abstract]. Am J Transplant 6[Suppl 2]: 429, 2006
51. Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J, Molinero L, Nozaki T, Phillips T, Uematsu S, Akira S, Wang CR, Fairchild RL, Alegre ML, Chong A: TLR engagement prevents transplantation tolerance. Am J Transplant 6: 2282-2291, 2006
52. Shen X, Ke B, Zhai Y, Gao F, Tsuchihashi S, Lassman CR, Busuttil RW, Kupiec-Weglinski JW: The absence of TLR4 signalling in the donor organ reduces ischemia and reperfusion injury in transplant recipients [Abstract]. Am J Transplant 6[Suppl 2]: 364, 2006
53. Shen X, Qiao B, Busuttil RW, Volk DH, Zhai Y, Kupiec-Weglinski JW: Direct evidence for the pivotal role of endogenous TLR4 signalling in the pathophysiology of liver ischemia and reperfusion injury [Abstract]. Am J Transplant 6[Suppl 2]: 364, 2006
54. Wu H, Chen G, Wyburn KB, Afifi M, Yin J, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia reperfusion injury [Abstract]. Am J Transplant 6[Suppl 2]: 371-372, 2006
55. Kawai T, Sachs DH, Spitzer T, Tolkoff-Rubin N, Shaffer J, Saidman S, Williams W, Dey B, Goes N, Ko D, Hertl M, Cotter P, Wong W, Colvin RB, Sykes M, Cosimi AB: Successful induction of renal allograft tolerance in HLA-mismatched kidney transplant recipients [Abstract]. Am J Transplant 6[Suppl 21: 169, 2006
56. Knechtle SJ, Sollinger HW, Jankowska-Gan E, Burlingham WJ, Bloom DD: Preliminary results of a tolerance trial in renal transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 171, 2006
57. Zilvetti MA, Trzonkowski P, Brockmann J, Darby C, Vaidya A, Devaney A, Simmonds M, Wood K, Friend PJ: Alemtuzumab enables steroid avoidance and calcineurin-inhibitor minimisation after kidney transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 290, 2006
58. Stevens RB, Grant W, Botha J, Sudan D, Langnas A, Wrenshall LE: Single-dose rabbit anti-thymocyte globulin induction with steroid avoidance and calcineurin-inhibitor withdrawal in renal transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 494, 2006
59. Turmelle YP, Shepherd RW, Nadler M, Kotru A, Lowell J: Towards minimizing immunosuppression in pediatric liver transplantation [Abstract]. Am J Transplant 6[Suppl 2]: 984, 2006
60. Karim M, Bushell AR, Wood KJ: Regulatory T cells in transplantation. Curr Opin Immunol 14: 584-591, 2002
61. Gao W, Oukka M, Kuchroo VK, Strom TB: Contrasting effects of cyclosporin and rapamycin in de novo generation of alloantigen-stimulated regulatory T cells [Abstract]. Am J Transplant 6[Suppl 2]: 79, 2006
62. ElEssawy B, Gao W, Liu P, Oukka M, Kuchroo VK, Strom TB: Rapamycin not cyclosporine induces regulatory CD8+FoxP3+ cells [Abstract]. Am J Transplant 6[Suppl 2]: 80, 2006
63. Kawai M, Kitade H, Mathieu C, Waer M, Pirenne J: Differential effect of immunosuppressive drugs on the development of regulatory cells [Abstract]. Am J Transplant 6[Suppl 2]: 313, 2006
64. Lopez-Hoyos M, San Segundo D, Ruiz JC, Fernandez-Fresnedo G, Izquierdo M, Gomez-Alamillo C, Merino R, Rodrigo E, Palomar R, Arias M: Different effect of immunosuppression on blood natural Tregs cells in stable renal transplant patients [Abstract]. Am J Transplant 6[Suppl 2]: 482-483, 2006
65. Cravedi P, Casiraghi F, Todeschini M, Monteferrante G, Cugini D, Bontempelli M, Perico N, Noris M, Remuzzi G: Effects of sirolimus (SRL) versus cyclosporine (CsA) as maintenance therapy after Campath-1H induction on T cell alloreactivity in kidney transplant recipients [Abstract]. Am J Transplant 6[Suppl 2]: 171, 2006
66. Lee I, Wang L, Ozkaynak E, Tao R, Hancock WW: Retrovirally-transduced Foxp3+ T cells promote permanent survival of fully MHC-mismatched cardiac allografts in immunocompetent hosts [Abstract]. Am J Transplant 6[Suppl 2]: 310-311, 2006
67. Watson D, Zhang GY, Hu M, Wang YM, Fletcher JT, Sartor M, Alexander I, Alexander SI: FOXP3 transduced CD4 T cells exert dominant tolerance in a major mismatch skin transplant model [Abstract]. Am J Transplant 6[Suppl 2]: 313, 2006
68. Lan YY, Wang Z, Raimondi G, Wu W, De Creus A, Thomson AW: Alternatively activated dendritic cells differentially regulate Toll-like receptor, IL-10 and IL-12p70 expression, expand Foxp3+ T cells and promote long-term organ allograft survival [Abstract]. Am J Transplant 6[Suppl 2]: 181, 2006
69. Luo X, Yang H, Tarbell KV, Ding R, Steinman RM, Suthanthiran M: TGFbeta-1 induced beta cell specific regulatory T cells suppress autoimmune diabetes [Abstract]. Am J Transplant 6[Suppl 2]: 311, 2006
70. Noris M, Aiello S, Cassis L, Cassis P, Tomasoni S, Benigni A, Pezzotta A, Cavinato RA, Cugini D, Azzollini N, Mister M, Longaretti L, Thomson AW, Remuzzi G: DNIKK2-transfected dendritic cells induce a novel population of INOS-expressing CD4+CD25+ cells with tolerogenic properties in vitro and in vivo [Abstract]. Am J Transplant 6[Suppl 2]: 611, 2006
71. Jiang S, Gloshayan D, Tsang J, Game D, Leung E, Lombardi G, Lechler RI: Adoptive cell therapy using in-vitro generated human CD4+CD25high and CD4+CD25DIM regulatory T cells with indirect allospecificity to promote donor-specific transplantation tolerance [Abstract]. Am J Transplant 6[Suppl 2]: 312, 2006